Physician profile
Philip Kim
NPI 1376929034
$1,060.96
in general payments reported to CMS, 2019-2025
11 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $532 · 2023: $17.50 · 2024: $195 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $264.95 | 2022 | |
| Amgen INC. | $245.70 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $143.58 | 2022 | |
| Allergan, INC. | $123.82 | 2022 | |
| Astellas Pharma US INC | $100.24 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $54.69 | 2024-2025 | |
| Glaukos Corporation | $34.54 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $33.13 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $28.14 | 2025 | Tyrvaya |
| Thea Pharma INC. | $17.50 | 2023 | |
| Mallinckrodt Hospital Products INC. | $14.67 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.